<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841774</url>
  </required_header>
  <id_info>
    <org_study_id>CSC01</org_study_id>
    <nct_id>NCT02841774</nct_id>
  </id_info>
  <brief_title>High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV</brief_title>
  <acronym>HILLCLIMBER</acronym>
  <official_title>High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With Human Immunodeficiency Virus (HILLCLIMBER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Feinstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin&#xD;
      therapy (pravastatin 40mg daily) versus high-dose statin therapy (rosuvastatin 20-40mg daily)&#xD;
      in HIV-infected persons taking antiretroviral therapy (ART) who have coronary heart disease&#xD;
      (CHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HILLCLIMBER is a randomized, controlled, open-label phase II trial of moderate dose statin&#xD;
      therapy versus high-dose statin therapy in HIV-infected persons taking antiretroviral therapy&#xD;
      (ART) who have coronary heart disease (CHD).&#xD;
&#xD;
      All subjects will have an initial 2-week run-in period with pravastatin 40mg daily (Week 0 to&#xD;
      2). Subjects not demonstrating significant toxicity at week 2 will then be randomized to&#xD;
      rosuvastatin 20mg (high intensity dose group) versus continuing pravastatin 40mg daily&#xD;
      (moderate intensity group) for 12 weeks (Weeks 2 to 14). At week 6, those in the rosuvastatin&#xD;
      arm who do not demonstrate significant toxicity and whose LDL-c is &gt;60mg/dl and decreased by&#xD;
      less than 25% compared with week 2 will then have doses increased to rosuvastatin 40mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 2021</completion_date>
  <primary_completion_date type="Actual">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change in fasting LDL-cholesterol</measure>
    <time_frame>Week 2 and Week 14</time_frame>
    <description>Mean percent change in fasting LDL-cholesterol at Week 2 and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>14 weeks</time_frame>
    <description>Number of Grade 3 or above adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in fasting HDL-cholesterol</measure>
    <time_frame>Week 2 and Week 14</time_frame>
    <description>Mean percent change in fasting HDL-cholesterol at Week 2 and Week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in fasting Total Cholesterol</measure>
    <time_frame>Week 2 and Week 14</time_frame>
    <description>Mean percent change in fasting Total Cholesterol at Week 2 and Week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change in fasting Triglycerides</measure>
    <time_frame>Week 2 and Week 14</time_frame>
    <description>Mean percent change in fasting Triglycerides at Week 2 and Week 14</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Infection</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Moderate Intensity Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pravastatin 40mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin 20 - 40 mg daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>40mg daily (Weeks 2 - 14)</description>
    <arm_group_label>Moderate Intensity Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK &lt;+1.5 x ULN, and LDL-c is &gt;60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily</description>
    <arm_group_label>High Intensity Group</arm_group_label>
    <other_name>CRESTOR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  HIV RNA below the lower limit of assay detection within 12 months of study entry&#xD;
&#xD;
          -  1) Documented coronary heart disease (CHD): nonfatal MI, unrecognized MI, unstable&#xD;
             angina pectoris, and/or stable angina pectoris, as defined by the American Heart&#xD;
             Association Case Definitions for Acute Coronary Heart Disease in Epidemiology and&#xD;
             Clinical Research Studies, OR Or (2) Documented 10-year ASCVD risk of 15% or greater&#xD;
             based on the ACC/AHA ASCVD Risk Estimator&#xD;
&#xD;
          -  Negative serum or urine pregnancy test&#xD;
&#xD;
          -  Men and women age 18 to 75 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious illness or AIDS-related complication within 21 days of screening requiring&#xD;
             systemic treatment and/or hospitalization&#xD;
&#xD;
          -  No coronary heart disease (CHD) and 10-year ASCVD risk &lt;15.0%.&#xD;
&#xD;
          -  Not currently receiving antiretroviral therapy or taking any of the following&#xD;
             antiretroviral agents: atazanavir/ritonavir, lopinavir/ritonavir.&#xD;
&#xD;
          -  History of statin intolerance leading to discontinuation, dose decrease, or change to&#xD;
             less potent dose equivalent&#xD;
&#xD;
          -  Statin absolute contraindication&#xD;
&#xD;
          -  Current use of atorvastatin 20mg daily or greater or rosuvastatin 10mg daily or&#xD;
             greater&#xD;
&#xD;
          -  Chronic kidney disease stage 4 or greater (including dialysis)&#xD;
&#xD;
          -  Systolic heart failure with last documented LVEF &lt;35%&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Laboratory values obtained within 45 days prior to study entry:&#xD;
&#xD;
        LDL-c &lt;80 mg/dl while not on statin or LDL-c &lt;60 mg/dl while on statin ALT &gt; 3 x Upper&#xD;
        Limit of Normal (ULN) AST &gt; 3 x ULN Creatinine kinase (CK) &gt;3 x ULN (calculated creatinine&#xD;
        clearance (CrCl) &lt;50 mL/min, as estimated by the Cockcroft-Gault equation)&#xD;
&#xD;
          -  Life expectancy &lt;12 months&#xD;
&#xD;
          -  Prior organ transplant&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Inflammatory muscle disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Lloyd-Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Matthew Feinstein</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Preventive Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

